安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- UC Irvine Solid Tumor Trial: NVL-655 in Patients With Advanced NSCLC . . .
This Solid Tumor and Non-Small Cell Lung Cancer study at UC Irvine is now recruiting people ages 12 years and up Skip to main content and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the
- Ph I II Study of NVL-655 Patients with Advanced NSCLC and . . . - UCI Health
UCI Specialty Area: Cancer Principal Investigator: Misako Nagasaka Official Title Lung Melanoma skin Mycosis Fungoides Other Digestive Organ Other Endocrine System (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors Phase 1 will determine the RP2D and, if
- Biomarker-Specific Survival and Cost for Advanced NSCLC
Key Points Question What are the survival and medication cost for advanced non–small cell lung cancer by biomarker status? Findings In this cohort study using data from 26 635 patients, the median overall survival was 39 9 months for ALK rearrangement, 27 0 months for EGFR variation, and 12 to 16 months for 3 programmed cell death 1 ligand 1 (PD-L1) groups
- Final Overall Survival and Long-Term Safety of Lorlatinib in Patients . . .
Introduction: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance mutations We present the overall survival (OS) and long-term safety of lorlatinib in patients with advanced ALK-positive NSCLC from the final analyses of the pivotal phase 2 study
- Lung Clinical Trials - cancer. uci. edu
UCI 18-21: A Phase I II Study of Oral LOXO-292 in Patients with (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation Versus Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who Progressed on or After Treated with
- University of California Health Non-Small Cell Lung Cancer Clinical . . .
Do you qualify for these Non-Small Cell Lung Cancer studies? We offer 108 options at UC Irvine UCSF (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors at UC Davis UC Irvine NX-1607 in Adults With Advanced Malignancies
- Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung . . .
INTRODUCTION Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that can be aberrantly expressed in several tumor types In non-small cell lung cancer (NSCLC), chromosomal rearrangements involving the ALK gene loci on chromosome 2 are found in approximately 3 to 5 percent of NSCLC tumors [] The most common ALK rearrangement in NSCLC juxtaposes the 5' end of the echinoderm microtubule
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non . . .
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy recommended for patients with ALK-positive non–small cell lung cancer (NSCLC) 1 Lorlatinib is a brain-penetrant, third-generation ALK TKI that has greater coverage of ALK resistance mutations than second-generation ALK inhibitors 2,3 In the phase III CROWN study, lorlatinib showed
|
|
|